Medical/Pharmaceuticals
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China
BEIJING, March 1, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) to start ph...
2022-03-02 10:37
2532
WuXi Biologics Wins CMO Leadership Awards in All Six Core Categories for Fifth Consecutive Year
SHANGHAI, March 1, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, today announced that the company has won the 2022 CMO Leadership Awards in all six core categories (i.e., capabilities, compatibility, expertise, reliability, quality and service).2022 m...
2022-03-02 10:07
2439
ImmVira's breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China
SHENZHEN, China, March 1, 2022 /PRNewswire/ -- Following its robust safety data in the U.S. Phase I clinical study, ImmVira announced that its global first intravenous administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed first dosing onMarch 1, 2022 and initiate...
2022-03-02 09:07
1597
Vocera, now part of Stryker, introduces latest evolution in hands-free communication to help protect and connect healthcare workers
New Minibadge expands intuitive mobile solutions for care team collaboration and safety KALAMAZOO, Michigan, USA, March 1, 2022 /PRNewswire/ -- Vocera, now part of Stryker, a global leading medical technology company, introduced the new Minibadge, a wearable, voice-driven device that enables mobi...
2022-03-01 21:00
1701
Kintor Pharma Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US
SUZHOU, China, March 1, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826 ("...
2022-03-01 20:30
2262
PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT
SYDNEY, Feb. 28, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in combination with metformin and a ketogenic diet for the treatmen...
2022-02-28 21:00
2980
First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial
SYDNEY, Feb. 25, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in cohort ...
2022-02-25 22:04
3410
Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy
SEOUL, South Korea, Feb. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) announced the topline results of the phase 3 clinical trial for a triple combination therapy of Enavogliflozin, a new antidiabetic drug with the mechanism of SGLT-2 inhibitor, with Metformin and Gemigliptin. Enav...
2022-02-25 22:00
3708
Terumo and Corazon Sign Collaboration and Co-Marketing Agreement
SOMERSET, N.J., Feb. 25, 2022 /PRNewswire/ -- Terumo Health Outcomes, a division of Terumo Medical Corporation, a leading global medical device manufacturer, has signed a collaboration and co-marketing agreement with Corazon, Inc., a leader in providing consulting, recruitment, interim managemen...
2022-02-25 22:00
4064
PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial
DAEJEON, South Korea, Feb. 25, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the completion of last patient last visit in its Phase Ib combination trial for mTNBC (me...
2022-02-25 21:00
2769
HitGen has successfully completed a three-year collaboration with MTPC to discover novel hit compounds for multiple drug targets
CHENGDU, China, Feb. 24, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STAR-listed company, today announced that the company has successfully completed a three-year drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation ("MTPC"), a Japanese pharma...
2022-02-25 10:00
1928
SeekIn Receives CE Mark Approval for SeekInCare® Pan Cancer Early Detection Test
SHENZHEN, China, Feb. 24, 2022 /PRNewswire/ -- SeekIn Inc, the leader in blood-based cancer early detection and monitoring technology, today announced the CE (Conformité Européenne) Mark for SeekInCare® Cancer Detection Kit and is now ready to launch this test in European markets. Nearly 10 mill...
2022-02-24 21:34
2050
Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer
HONG KONG, Feb. 24, 2022 /PRNewswire/ -- On February 23 2022, Simcere Pharmaceutical Group (2096.HK) announced that the phase III clinical registration study of Trilaciclib in patients with extensive-stage small cell lung cancer (ES-SCLC) has met its primary endpoint. The drug co-developed in Chi...
2022-02-24 13:34
2087
Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China
BEIJING, SHANGHAI and BOSTON, Feb. 23, 2022 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) announced that its KRAS G12C inhibitor JAB-21822 completed the first patient dosing in combinationtherapy with Cetuximab at Peking University Cancer Hospital recently. JAB-21822 in combination with ce...
2022-02-24 10:32
2049
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
TAIPEI, Feb. 23, 2022 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), aTaiwan and US-based biopharmaceutical company and TRPharm, a leading Turkish healthcare company, announced today that they have entered into an exclusive license agreement for the co-development and ...
2022-02-23 23:00
2728
Simcere Pharma (2096.HK) Announces a Positive Profit Alert
HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group"; stock code: 2096.HK), announces a positive profit alert. Based on a preliminary assessment of the Group's unaudited consolidated management accounts for the ...
2022-02-23 16:22
3703
Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform
SUZHOU, China, and PALO ALTO, Calif., Feb. 22, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...
2022-02-22 20:30
2436
InnoCare Announces Dosing of First Patient in Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP
BEIJING, Feb. 22, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the first patient has been dosed in Phase II clinical trial of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of primary immune thrombocyto...
2022-02-22 17:09
2428
111 to Announce Fourth Quarter and Fiscal Year 2021 Unaudited Financial Results on March 17, 2022 - Conference Call to Follow
SHANGHAI, Feb. 22, 2022 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...
2022-02-22 16:38
2114
Winner Silver Alginate Dressing has Obtained 510K Code in the USA
SHENZHEN, China, Feb. 21, 2022 /PRNewswire/ -- Recently, the silver alginate dressing of Winner Medical (300888.SZ) receives U.S. FDA market access (510K Number: K202982), marking that this product has obtained the qualification to get into the access US market and Winner Medical will further e...
2022-02-22 10:10
2334
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 320 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Vizzio Technologies Strengthens Leadership As Global Growth Accelerates
[Picked up by 294 media titles]
2026-02-11 14:59
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 272 media titles]
2026-02-17 19:12
Most Read
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
6977
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
6737
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
2026-02-12 21:56
6034
